Pharmablock Sciences (Nanjing), Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Pharmablock (Nanjing) R&D Co. Ltd. (to 2016)
0
Ending by 2030
Nov 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 15, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,957,210 | Method for Synthesizing 1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-formamidine Hydrochloride In force · High confidence | In force | High confidence | |
| US 9,440,981 | Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,591,326 | Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,486,251 | CBP/EP300 inhibitor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,479,846 | EZH2 inhibitor and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,729,192 | CDK9 Inhibitor and Use Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.